Клиническая характеристика пациента с первичным психозом, направленная на персонализацию ведения
Всемирная психиатрия. №1 2021
Клиническая характеристика пациента с первичным психозом, направленная на персонализацию ведения
Mario Maj1 , Jim van Os2-4, Marc De Hert5,6, Wolfgang Gaebel7 , Silvana Galderisi1 , Michael F. Green8,9, Sinan Guloksuz3,10, Philip D. Harvey11, Peter B. Jones12, Dolores Malaspina13, Patrick McGorry14,15, Jouko Miettunen16,17, Robin M. Murray4 , Keith H. Nuechterlein18, Victor Peralta19, Graham Thornicroft20, Ruud van Winkel3,6,21, Joseph Ventura8
Department of Psychiatry, University of Campania “L. Vanvitelli”, Naples, Italy; 2 Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands; 3 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maas- tricht University Medical Center, Maastricht, The Netherlands; 4 Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 5 University Psychiatric Centre KU Leuven, Kortenberg, Belgium; 6 Antwerp Health Law and Ethics Chair, University of Antwerp, Antwerp, Belgium; 7 De- partment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf, LVR-Klinikum Düsseldorf, and WHO Collaborating Center on Quality Assurance and Empowerment in Mental Health, Düsseldorf, Germany; 8 Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA; 9 Department of Veterans Affairs, Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA; 10Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 11Di- vision of Psychology, Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA; 12Department of Psychiatry, University of Cambridge and Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK; 13Department of Psychiatry and Neuroscience, Ichan Med- ical School at Mount Sinai, New York, NY, USA; 14Orygen, Parkville, VIC, Australia; 15Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia; 16Centre for Life Course Health Research, University of Oulu, Oulu, Finland; 17Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; 18Semel Institute for Neuroscience and Human Behavior, Geffen School of Medicine, and Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA; 19Mental Health Department, Servicio Navarro de Salud, Instituto de Investi- gación Sanitaria de Navarra, Pamplona, Spain; 20Centre for Global Mental Health and Centre for Implementation Science, Institute of Psychiatry, Psy- chology & Neuroscience, King’s College London, London, UK; 21University Psychiatric Center KU Leuven, Leuven, Belgium
Стр. 4-33
900 просмотров
Опубликовано: 1 февраля 2021
Аннотация / Abstract
a:2:{s:4:"TEXT";s:65533:"a:2:{s:4:"TYPE";s:4:"HTML";s:4:"TEXT";s:109921:"Первичные психозы представляют собой неоднородную группу психических расстройств, которые: а) характеризуются бредом и/или галлюцинациями, наряду с другими клиническими проявлениями, такими как дезорганизация мышления, грубо дезорганизованная или патологическая моторная активность и негативные симптомы (например, аффективное уплощение, алогия, асоциальность, ангедония или аволиция); б) не вызваны воздействием на центральную нервную систему психоактивных веществ или лекарственных средств и не являются следствием других заболеваний (например, опухоли мозга или аутоиммунных заболеваний) или расстройства настроения (депрессии или мании).Действующие системы классификаций болезней, DSM-5 1 и МКБ-11 2 , содержат несколько категорий, соответствующих приведенному выше определению, но ни перечень данных категорий, ни их определения не являются единообразными в двух системах.В DSM-5 первичные психозы включают в себя шизофрению, шизофреноформное расстройство, кратковременное психотическое расстройство, шизоаффективное расстройство, бредовое расстройство, «другое уточненное расстройство шизофренического спектра и другое психотическое расстройство» и «неуточненное расстройство шизофренического спектра и другое психотическое расстройство». В МКБ-11 первичные психозы (выражение «первичные психотические расстройства» широко используется в данной системе) включают шизофрению, острое и транзиторное психотические расстройства, шизоаффективное расстройство, бредовое расстройство и «другое первичное психотическое расстройство».В DSM-5 определение шизофрении требует «наличия постоянных признаков нарушений по крайней мере в течение 6 мес», при этом данное требование отсутствует в МКБ-11 (определено лишь, что «симптомы должны проявляться большую часть времени в течение 1 мес или дольше»). Как следствие, категория шизофреноформного расстройства из DSM-5 (характеризующегося продолжительность...
Первичные психозы представляют собой неоднородную группу психических расстройств, которые: а) характеризуются бредом и/или галлюцинациями, наряду с другими клиническими проявлениями, такими как дезорганизация мышления, грубо дезорганизованная или патологическая моторная активность и негативные симптомы (например, аффективное уплощение, алогия, асоциальность, ангедония или аволиция); б) не вызваны воздействием на центральную нервную систему психоактивных веществ или лекарственных средств и не являются следствием других заболеваний (например, опухоли мозга или аутоиммунных заболеваний) или расстройства настроения (депрессии или мании).Действующие системы классификаций болезней, DSM-5 1 и МКБ-11 2 , содержат несколько категорий, соответствующих приведенному выше определению, но ни перечень д...
Материал для специалистов
Полный текст статьи доступен только зарегистрированным пользователям.
Вход / Регистрация- 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
- 2. World Health Organization. ICD-11 guidelines. https://gcp.network/en/.
- 3. Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry 2019;18:146-61.
- 4. Sartorius N, Chiu H, Heok KE et al. Name change for schizophrenia. Schizophr Bull 2014;40:255-8.
- 5. Perälä J, Suvisaari J, Saarni SI et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28.
- 6. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
- 7. Bighelli I, Salanti G, Huhn M et al. Psychological interventions to reduce positive symptoms in schizophrenia: a systematic review and network meta-analysis. World Psychiatry 2018;17:316-29.
- 8. Drake RE, Essock SM. The science-to-service gap in real-world schizophrenia treatment: the 95% problem. Schizophr Bull 2009;35:677-8.
- 9. McFarlane WR. Family interventions for schizophrenia and the psychoses: a review. Family Process 2016;55:460-82.
- 10. Bond GR, Becker DR, Drake RE et al. Implementing supported employment as an evidence-based practice. Psychiatr Serv 2001; 52:313-22.
- 11. De Hert M, Detraux J. Reversing the downward spiral for people with severe mental illness through educational innovations. World Psychiatry 2017;16:41-2.
- 12. Fleischhacker WW, Arango C, Arteel P et al. Schizophrenia – time to commit to policy change. Schizophr Bull 2014;40(Suppl. 3):S165-94.
- 13. Pincus HA, Spaeth-Rublee B, Grant S et al. A review of mental health recovery programs in selected industrialized countries. Int J Ment Health Syst 2016;10:73.
- 14. Maj M, Stein DJ, Parker G et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269-93.
- 15. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry 2018;31:32-9.
- 16. Sass LA. Self-disturbance and schizophrenia: structure, specificity, pathogenesis (current issues, new directions). Schizophr Res 2014;152:5-11.
- 17. Parnas J. The core Gestalt of schizophrenia. World Psychiatry 2012;11:67-9.
- 18. Parnas J, Møller P, Kircher T et al. EASE: Examination of Anomalous Self-Experience. Psychopathology 2005;38:236-58.
- 19. Nordgaard J, Parnas J. Self-disorders and the schizophrenia spectrum: a study of 100 first hospital admissions. Schizophr Bull 2014;40:1300-7.
- 20. Cicero DC, Neis AM, Klaunig MJ et al. The Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE): development and validation. Psychol Assess 2017;29:13-25.
- 21. Nelson B, Li E, Cicero DC et al. The construct validity of the Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE) as a measure of minimal self-disturbance: preliminary data. Early Interv Psychiatry 2019;13:686-91.
- 22. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39:964-71.
- 23. Konings M, Bak M, Hanssen M et al. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand 2006;114:55-61.
- 24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
- 25. Kay SR, Opler RA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) manual. Toronto: Multi-Health Systems Inc., 2000.
- 26. Ostergaard SD, Lemming OM, Mors O et al. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand 2016;133:436-44.
- 27. Lincoln TM, Ziegler M, Lüllmann E et al. Can delusions be self-assessed? Concordance between self- and observer-rated delusions in schizophrenia. Psychiatry Res 2010;178:249-54.
- 28. Carey TA, Mullan RJ. What is Socratic questioning? Psychother Theor Res Pract Train 2004;41:217-26.
- 29. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394:939-51.
- 30. Howes OD, McCutcheon R, Agid O et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-29.
- 31. Gaebel W, Stricker J, Riesbeck M. The long-term antipsychotic treatment of schizophrenia: a selective review of clinical guidelines and clinical case examples. Schizophr Res (in press).
- 32. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 2018;17:149-60.
- 33. Murray RM, Quattrone D, Natesan S et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016;209:361-5.
- 34. Palmier-Claus J, Griffiths R, Murphy E et al. Cognitive behavioural therapy for thought disorder in psychosis. Psychosis 2017;9:347-57.
- 35. Trower P, Birchwood M, Meaden A et al. Cognitive therapy for command hallucinations: randomised controlled trial. Br J Psychiatry 2004;184:312-20.
- 36. Peters ER, Moritz S, Schwannauer M et al. Cognitive Biases Questionnaire for psychosis. Schizophr Bull 2014;40:300-13.
- 37. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke, 1911.
- 38. Jackson JH. Selected writings. London: Hodder and Stoughton, 1931.
- 39. Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry 2012;11:73-9.
- 40. Galderisi S, Rossi A, Rocca P et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 2014;13:275-87.
- 41. Galderisi S, Mucci A, Buchanan RW et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry 2018;5:664-77.
- 42. Kirkpatrick B, Fenton WS, Carpenter WT Jr et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19.
- 43. Strauss GP, Esfahlani FZ, Galderisi S et al. Network analysis reveals the latent structure of negative symptoms in schizophrenia. Schizophr Bull 2019;45:1033-41.
- 44. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017;16:14-24.
- 45. Mucci A, Merlotti E, Üçok A et al. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res 2017;186:19-28.
- 46. Krause M, Zhu Y, Huhn M et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018;268:625-39.
- 47. Lutgens D, Gariepy G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;210:324-32.
- 48. Turner DT, McGlanaghy E, Cuijpers P et al. A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 2018;44:475-91.
- 49. Velthorst E, Koeter M, van der Gaag M et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med 2015;45:453-65.
- 50. Cella M, Preti A, Edwards C et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev 2017;52:43-51.
- 51. Kennedy NI, Lee WH, Frangou S. Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry 2018;49:69-77.
- 52. Andreasen NC, Olsen S. Negative vs positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789-94.
- 53. Kirkpatrick B, Strauss GP, Nguyen L et al. The brief negative symptom scale: psychometric properties. Schizophr Bull 2011;37:300-5.
- 54. Kring AM, Gur RE, Blanchard JJ et al. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry 2013;170:165-72.
- 55. Peralta V, Gil-Berrozpe G, Librero J et al. The symptom and domain structure of psychotic disorders: a network analysis approach. Schizophr Bull Open (in press).
- 56. Minor KS, Lysaker PH. Necessary, but not sufficient: links between neurocognition, social cognition, and metacognition in schizophrenia are moderated by disorganized symptoms. Schizophr Res 2014;159:198-204.
- 57. Rocca P, Galderisi S, Rossi A et al. Disorganization and real-world functioning in schizophrenia: results from the multicenter study of the Italian Network for Research on Psychoses. Schizophr Res 2018;201:105-12.
- 58. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-23.
- 59. Broome MR, Bottlender R, Rossler M. et al (eds). The AMDP System. Manual for assessment and documentation of psychopathology in psychiatry, 9th ed Boston: Hogrefe, 2018.
- 60. Andreasen NC. Scale for the assessment of thought, language, and communication (TLC). Schizophr Bull 1986;12:473-82.
- 61. Peralta V, Cuesta MJ. Motor abnormalities: from neurodevelopmental to neurodegenerative through «functional» (neuro)psychiatric disorders. Schizophr Bull 2017;43:956-71.
- 62. Bush G, Fink M, Petrides G et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-36.
- 63. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: US Department of Health, Education and Welfare, 1976.
- 64. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(Suppl. 212):11-9.
- 65. Gerlach J, Korsgaard S, Clemmesen P et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87:244-52.
- 66. Martino D, Karnik V, Osland S et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry 2018;63:730-9.
- 67. Peralta V, Cuesta MJ. Characterization of affective domains within the nonaffective psychotic disorders. Schizophr Res 2009;111:61-9.
- 68. Gonzalez-Pinto A, Gutierrez M, Mosquera F et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 1998;50:41-4.
- 69. Addington D, Addington J, Maticka-Tyndale E et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-8.
- 70. Lysaker PH, Pattison ML, Leonhardt BL et al. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 2018;17:12-23.
- 71. Amador XF, Strauss DH, Yale SA et al. Assessment of insight in psychosis. Am J Psychiatry 1993;150:873-9.
- 72. Beck AT, Baruch E, Balter JM et al. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res 2004;68:319-29.
- 73. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24(Suppl. 4):81-90.
- 74. Posner K, Brown GK, Stanley B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
- 75. Breslau N, Roth T, Rosenthal L et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8.
- 76. Xiang YT, Weng YZ, Leung CM et al. Prevalence and correlates of insomnia and its impact on quality of life in Chinese schizophrenia patients. Sleep 2009;32:1059.
- 77. Alam A, Chengappa KR, Ghinassi F. Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. Gen Hosp Psychiatry 2012;34:660-4.
- 78. van Os J, Reininghaus U. The clinical epidemiology of schizophrenia In: Kaplan B, Sadock J, Sadock V. et al (eds). Kaplan & Sadock’s comprehensive textbook of psychiatry, 10th ed London: Lippincott Williams & Wilkins, 2017.
- 79. Singh SP, Cooper JE, Fisher HL et al. Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). Schizophr Res 2005;80:117-30.
- 80. Perkins DO, Leserman J, Jarskog LF et al. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 2000;44:1-10.
- 81. Sartorius N, Shapiro R, Kimura M et al. WHO International Pilot Study of Schizophrenia. Psychol Med 1972;2:422-5.
- 82. Johnstone EC, Frith CD, Crow TJ et al. The Northwick Park ’Functional' Psychosis Study: diagnosis and outcome. Psychol Med 1992;22:331-46.
- 83. Tsuang MT, Dempsey GM. Long-term outcome of major psychoses. II. Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1979;36:1302-4.
- 84. Susser E, Finnerty M, Mojtabai R et al. Reliability of the Life Chart Schedule for assessment of the long-term course of schizophrenia. Schizophr Res 2000;42:67-77.
- 85. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006;36:1349-62.
- 86. Llewellyn-Beardsley J, Rennick-Egglestone S, Callard F et al. Characteristics of mental health recovery narratives: systematic review and narrative synthesis. PLoS One 2019;14:e0214678.
- 87. Corrigan PW, Salzer M, Ralph RO et al. Examining the factor structure of the Recovery Assessment Scale. Schizophr Bull 2004;30:1035-41.
- 88. Carter L, Read J, Pyle M et al. The impact of causal explanations on outcome in people experiencing psychosis: a systematic review. Clin Psychol Psychother 2017;24:332-47.
- 89. Nuechterlein KH, Green MF, Kern R. Schizophrenia as a cognitive disorder: recent approaches to identifying its core cognitive components to aid treatment development In: Gattaz WF, Busatto G. (eds). Advances in schizophrenia research 2009. New York: Springer, 2009:267-82.
- 90. Cornblatt B, Obuchowski M, Roberts S et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999;11:487-508.
- 91. Nuechterlein KH, Dawson ME, Gitlin M et al. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 1992;18:387-425.
- 92. Snitz BE, MacDonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179-94.
- 93. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
- 94. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72:5-9.
- 95. Nuechterlein KH, Barch DM, Gold JM et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39.
- 96. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45.
- 97. Kern RS, Gold JM, Dickinson D et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 2011;126:124-31.
- 98. Grant PM, Best MW, Beck AT. The meaning of group differences in cognitive test performance. World Psychiatry 2019;18:163-4.
- 99. Green MF, Kern RS, Braff DL et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000;26:119-36.
- 100. Fett AKJ, Viechtbauer W, Dominguez MG et al. The relationship between neurocognition and social cognition and functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573-88.
- 101. Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 2008;165:203-13.
- 102. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery Manual, 3rd ed. Los Angeles: MATRICS Assessment, Inc., 2016.
- 103. Robbins TW, James M, Owen AM et al. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-81.
- 104. Pietrzak RH, Olver J, Norman T et al. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009;31:848-59.
- 105. Keefe RSE, Goldberg TE, Harvey PD et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283-97.
- 106. Randolph C, Tierney MC, Mohr E et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-9.
- 107. Velligan DI, DiCocco M, Bow-Thomas CC et al. A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res 2004;71:273-83.
- 108. Hurford IM, Marder SR, Keefe RS et al. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull 2011;37:538-45.
- 109. Ventura J, Reise SP, Keefe RS et al. The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophr Bull 2013;39:583-91.
- 110. Keefe RS, Poe M, Walker TM et al. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 2006;163:426-32.
- 111. Wykes T, Huddy V, Cellard C et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011;168:472-85.
- 112. Firth J, Stubbs B, Rosenbaum S et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2017;43:546-56.
- 113. Nuechterlein KH, Ventura J, McEwen SC et al. Enhancing cognitive training through aerobic exercise after a first schizophrenia episode: theoretical conception and pilot study. Schizophr Bull 2016;42(Suppl. 1):S44-52.
- 114. Best MW, Milanovic M, Iftene F et al. A randomized controlled trial of executive functioning training compared with perceptual training for schizophrenia spectrum disorders: effects on neurophysiology, neurocognition, and functioning. Am J Psychiatry 2019;176:297-306.
- 115. Medalia A, Saperstein AM, Qian M et al. Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophr Res 2019;208:397-405.
- 116. Green MF, Penn DL, Bentall R et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull 2008;34:1211-20.
- 117. Savla GN, Vella L, Armstrong CC et al. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull 2013;39:979-92.
- 118. Healey KM, Bartholomeusz CF, Penn DL. Deficits in social cognition in first episode psychosis: a review of the literature. Clin Psychol Rev 2016;50:108-37.
- 119. Nahum M, Fisher M, Loewy R et al. A novel, online social cognitive training program for young adults with schizophrenia: a pilot study. Schizophr Res Cogn 2014;1:e11-9.
- 120. Kurtz MM, Gagen E, Rocha NBF et al. Comprehensive treatments for social cognitive deficits in schizophrenia: a critical review and effect-size analysis of controlled studies. Clin Psychol Rev 2016;43:80-9.
- 121. Horan WP, Dolinsky M, Lee J et al. Social cognitive skills training for psychosis with community-based training exercises: a randomized controlled trial. Schizophr Bull 2018;44:1254-66.
- 122. Burkner PC, Williams DR, Simmons TC et al. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull 2017;43:1291-303.
- 123. Davis MC, Green MF, Lee J et al. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014;39:2070-7.
- 124. Pinkham AE, Penn DL, Green MF et al. Social cognition psychometric evaluation: results of the Initial Psychometric Study. Schizophr Bull 2016;42:494-504.
- 125. Kern RS, Penn DL, Lee J et al. Adapting social neuroscience measures for schizophrenia clinical trials, part 2: Trolling the depths of psychometric properties. Schizophr Bull 2013;39:1201-10.
- 126. Horan WP, Green MF. Treatment of social cognition in schizophrenia: current status and future directions. Schizophr Res 2019;203:3-11.
- 127. McDonald S, Flanagan S, Rollins J. The Awareness of Social Inference Test. Suffolk: Thames Valley Test Company, 2002.
- 128. Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) user’s manual. Toronto: MHS Publishers, 2002.
- 129. Bryson G, Bell M, Lysaker P. Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. Psychiatry Res 1997;71:105-13.
- 130. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. Fünfte, vollständig umgearbeitete Auflage. Leipzig: Barth, 1896.
- 131. Fish B. The detection of schizophrenia in infancy: a preliminary report. J Nerv Ment Dis 1957;125:1-24.
- 132. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
- 133. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ 1987;295:681-2.
- 134. Jones P, Rodgers B, Murray R et al. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344:1398-402.
- 135. Isohanni M, Jones PB, Moilanen K et al. Early developmental milestones in adult schizophrenia and other psychoses. A 31-year follow-up of the Northern Finland 1966 Birth Cohort. Schizophr Res 2001;52:1-19.
- 136. Cannon M, Caspi A, Moffitt TE et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002;59:449-56.
- 137. Khandaker GM, Barnett JH, White IR et al. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res 2011;132:220-7.
- 138. Heinrichs DW, Buchanan RW. Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry 1988;145:11-8.
- 139. Fish B, Marcus J, Hans SL et al. Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. Arch Gen Psychiatry 1992;49:221-35.
- 140. Green MF, Satz P, Christenson C. Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings. Schizophr Bull 1994;20:433-40.
- 141. Larson FV, Wagner AP, Jones PB et al. Psychosis in autism: comparison of the features of both conditions in a dually affected cohort. Br J Psychiatry 2017;210:269-75.
- 142. Downs JM, Lechler S, Dean H et al. The association between comorbid autism spectrum disorders and antipsychotic treatment failure in early-onset psychosis: a historical cohort study using electronic health records. J Clin Psychiatry 2017;78:e1233-41.
- 143. Khandaker GM, Stochl J, Zammit S et al. A population-based longitudinal study of childhood neurodevelopmental disorders, IQ and subsequent risk of psychotic experiences in adolescence. Psychol Med 2014;44:3229-38.
- 144. Sanders RD, Keshavan MS. The neurologic examination in adult psychiatry: from soft signs to hard science. J Neuropsychiatry Clin Neurosci 1998;10:395-404.
- 145. Chen EY, Shapleske J, Luque R et al. The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995;56:183-204.
- 146. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 1989;27:335-50.
- 147. Cannon-Spoor H, Potkin S, Wyatt R. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470-84.
- 148. Van Mastrigt S, Addington J. Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. J Psychiatry Neurosci 2002;27:92-101.
- 149. Leung WW, Bowie CR, Harvey PD. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J Int Neuropsychol Soc 2008;14:479-88.
- 150. Granholm E, Holden JL, Mikhael T et al. What do people with schizophrenia do all day? Ecological momentary assessment of real-world functioning in schizophrenia. Schizophr Bull 2020;46:242-51.
- 151. Gard DE, Kring AM, Gard MG et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 2007;93:253-60.
- 152. Sitzer DI, Twamley EW, Patterson TL et al. Multivariate predictors of social skills performance in middle-aged and older out-patients with schizophrenia spectrum disorders. Psychol Med 2008;38: 755-63.
- 153. Robertson BR, Prestia D, Twamley EW et al. Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res 2014;160:136-41.
- 154. Granholm E, Holden J, Link PC et al. Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms. J Consult Clin Psychol 2014;82:1173-85.
- 155. Harvey PD, Raykov T, Twamley EW et al. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry 2011;168:1195-201.
- 156. Morosini PL, Magliano L, Brambilla L et al. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9.
- 157. Gard DE, Gard MG, Kring AM et al. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers 2006;40:1086-102.
- 158. Llerena K, Park SG, McCarthy JM et al. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry 2013;54:568-74.
- 159. Schlosser DA, Campellone TR, Truong B et al. Efficacy of PRIME, a mobile app intervention designed to improve motivation in young people with schizophrenia. Schizophr Bull 2018;44:1010-20.
- 160. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull 2012;38:304-15.
- 161. Durand D, Strassnig M, Sabbag S et al. Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies. Eur Neuropsychopharmacol 2015;25:185-91.
- 162. World Health Organization. The World Health Organization Quality of Life (WHOQOL). www.who.int.
- 163. Button B. Quality of Well-Being (QWB) Scale In: Michalos AC. (eds). Encyclopedia of quality of life and well-being research. Dordrecht: Springer, 2016.
- 164. Slade M, Leese M, Ruggeri M et al. Does meeting needs improve quality of life? Psychother Psychosom 2004;73:183-9.
- 165. Drukker M, van Dillen K, Bak M et al. The use of the Camberwell Assessment of Need in treatment: what unmet needs can be met? Soc Psychiatry Psychiatr Epidemiol 2008;43:410-7.
- 166. Maslow AH. Toward a psychology of being. Princeton: Van Nostrand, 1962.
- 167. Lasalvia A, Bonetto C, Tansella M et al. Does staff-patient agreement on needs for care predict a better mental health outcome? A 4-year follow-up in a community service. Psychol Med 2008;38:123-33.
- 168. Puschner B, Becker T, Mayer B et al. Clinical decision making and outcome in the routine care of people with severe mental illness across Europe (CEDAR). Epidemiol Psychiatr Sci 2016;25:69-79.
- 169. Drukker M, Joore M, van Os J et al. The use of a cumulative needs for care monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective. Epidemiol Psychiatr Sci 2012;21:381-92.
- 170. Drukker M, van Os J, Dietvorst M et al. Does monitoring need for care in patients diagnosed with severe mental illness impact on psychiatric service use? Comparison of monitored patients with matched controls. BMC Psychiatry 2011;11:45.
- 171. Drukker M, van Os J, Bak M et al. Systematic monitoring of needs for care and global outcomes in patients with severe mental illness. BMC Psychiatry 2010;10:36.
- 172. Slade M, Phelan M, Thornicroft G et al. The Camberwell Assessment of Need (CAN): comparison of assessments by staff and patients of the needs of the severely mentally ill. Soc Psychiatry Psychiatr Epidemiol 1996;31:109-13.
- 173. Phelan M, Slade M, Thornicroft G et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry 1995;167:589-95.
- 174. Bond GR, Drake RE, Becker DR. An update on Individual Placement and Support. World Psychiatry 2020;19:390-1.
- 175. McGorry PD, Hickie IB. (eds). Clinical staging in psychiatry: making diagnosis work for research and treatment. Cambridge: Cambridge University Press, 2019.
- 176. McGorry PD, Hickie IB, Yung AR et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006;40:616-22.
- 177. Shah JL, Scott J, McGorry PD et al. Transdiagnostic clinical staging in youth mental health: a first international consensus statement. World Psychiatry 2020;19:233-42.
- 178. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993;87:225-30.
- 179. McGorry PD, Hartmann JA, Spooner R et al. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry 2018;17:133-42.
- 180. McGorry PD, Ratheesh A, O’Donoghue B. Early intervention – an implementation challenge for 21st century mental health care. JAMA Psychiatry 2018;75:545-6.
- 181. Correll CU, Galling B, Pawar A et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 2018;75:555-65.
- 182. Frances A. Saving normal: an insider’s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. New York: Morrow, 2013.
- 183. Insel TR. The arrival of preemptive psychiatry. Early Interv Psychiatry 2007;1:5-6.
- 184. Hegelstad WT, Larsen TK, Auestad B et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry 2012;169:374-80.
- 185. Kane JM, Robinson DG, Schooler NR et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry 2016;173:362-72.
- 186. Francey S, O’Donoghue B, Nelson B et al. Psychosocial intervention with or without antipsychotic medication for first episode psychosis: a randomized noninferiority clinical trial. Schizophr Bull Open (in press).
- 187. Orygen . Australian clinical guidelines for early psychosis, 2nd ed Melbourne: Orygen, The National Centre of Excellence in Youth Mental Health, 2016.
- 188. Thien K, Bowtell M, Eaton S et al. Clozapine use in early psychosis. Schizophr Res 2018;199:374-9.
- 189. Killackey E, Allott K, Jackson HJ et al. Individual placement and support for vocational recovery in first-episode psychosis: randomised controlled trial. Br J Psychiatry 2019;214:76-82.
- 190. Wunderink L, Nieboer RM, Wiersma D et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913-20.
- 191. First MB, Williams JBW, Karg RS et al. Structured Clinical Interview for DSM-5 – Research Version. Arlington: American Psychiatric Association, 2015.
- 192. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull 2017;43:240-4.
- 193. Heimberg RG, Horner KJ, Juster HR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212.
- 194. Sharma LP, Reddy YCJ. Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. Indian J Psychiatry 2019;61(Suppl. 1):S140-8.
- 195. Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
- 196. Malaspina D, Walsh-Messinger J, Brunner A et al. Features of schizophrenia following premorbid eating disorders. Psychiatry Res 2019;278:275-80.
- 197. Peralta V, de Jalón EG, Campos MS et al. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr Res 2011;126:28-35.
- 198. Hartz SM, Pato CN, Medeiros H et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71:248-54.
- 199. Hare RD. The Hare Psychopathy Checklist-Revised. North Tonawanda: Multi-Health Systems, 1991.
- 200. Oakley P, Kisely S, Baxter A, et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 2018;102:245-53.
- 201. De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
- 202. Correll CU, Detraux J, De Lepeleire J et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-36.
- 203. Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675-712.
- 204. Vancampfort D, Stubbs B, Mitchell AJ et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47.
- 205. De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 2018;20:31-40.
- 206. Vancampfort D, Correll CU, Galling B et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74.
- 207. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-80.
- 208. De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138-51.
- 209. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138:e426-83.
- 210. Garg N, Muduli SK, Kapoor A et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J 2017;69:458-63.
- 211. WHO CVD Risk Chart Working Group . World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332-45.
- 212. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
- 213. Yusuf S, Joseph P, Rangarajan S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020;395:795-808.
- 214. Rosengren A, Hawken S, Ounpuu S et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:953-62.
- 215. Vancampfort D, Firth J, Schuch FB et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017;16:308-15.
- 216. Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol 2015;2015:969182.
- 217. Vancampfort D, Firth J, Correll CU et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019;18:53-66.
- 218. Tumiel E, Wichniak A, Jarema M et al. Nonpharmacological interventions for the treatment of cardiometabolic risk factors in people with schizophrenia – a systematic review. Front Psychiatry 2019;10:566.
- 219. Luo F, Das A, Chen J et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol 2019;18:54.
- 220. McGinty EE, Baller J, Azrin ST et al. Interventions to address medical conditions and health risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 2016;42:96-124.
- 221. Shawen AE, Drayton SJ. Review of pharmacotherapy for smoking cessation in patients with schizophrenia. Ment Health Clin 2018;8:78-85.
- 222. Gates J, Killackey E, Phillips L et al. Mental health starts with physical health: current status and future directions of non-pharmacological interventions to improve physical health in first-episode psychosis. Lancet Psychiatry 2015;2:726-42.
- 223. Torous J, Andersson G, Bertagnoli A et al. Towards a consensus around standards for smartphone apps and digital mental health. World Psychiatry 2019;18:97-8.
- 224. Rasic D, Hajek T, Alda M et al. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull 2014;40:28-38.
- 225. Yang J, Visscher PM, Wray NR. Sporadic cases are the norm for complex disease. Eur J Hum Genet 2010;18:1039-43.
- 226. Mortensen PB, Pedersen MG, Pedersen CB. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? Psychol Med 2010;40:201-10.
- 227. Cross-Disorder Group of the Psychiatric Genomics Consortium , Lee SH, Ripke S et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45:984-94.
- 228. Cross-Disorder Group of the Psychiatric Genomics Consortium, Genetic Risk Outcome of Psychosis Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9.
- 229. Agerbo E, Sullivan PF, Vilhjalmsson BJ et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. JAMA Psychiatry 2015;72:635-41.
- 230. Vigod SN, Kurdyak PA, Dennis CL et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. BJOG 2014;121:566-74.
- 231. Zhong QY, Gelaye B, Fricchione GL et al. Adverse obstetric and neonatal outcomes complicated by psychosis among pregnant women in the United States. BMC Pregnancy Childbirth 2018;18:120.
- 232. Gantriis DL, Thorup AAE, Harder S et al. Home visits in the Danish High Risk and Resilience Study – VIA 7: assessment of the home environment of 508 7-year-old children born to parents diagnosed with schizophrenia or bipolar disorder. Acta Psychiatr Scand 2019;140:126-34.
- 233. Simoila L, Isometsa E, Gissler M et al. Maternal schizophrenia and out-of-home placements of offspring: a national follow-up study among Finnish women born 1965-1980 and their children. Psychiatry Res 2019;273:9-14.
- 234. de Sousa P, Varese F, Sellwood W et al. Parental communication and psychosis: a meta-analysis. Schizophr Bull 2014;40:756-68.
- 235. Ranning A, Laursen T, Agerbo E et al. School performance from primary education in the adolescent offspring of parents with schizophrenia and bipolar disorder – a national, register-based study. Psychol Med 2018;48:1993-2000.
- 236. Kallquist A, Salzmann-Erikson M. Experiences of having a parent with serious mental illness: an interpretive meta-synthesis of qualitative literature. J Child Fam Stud 2019;28:2056-68.
- 237. NIMH Genetics Initiative. Family Interview for Genetic Studies (FIGS). Rockville: National Institute of Mental Health, 1992.
- 238. Nurnberger JI Jr, Blehar MC, Kaufmann CA et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-59.
- 239. Weissman MM, Wickramaratne P, Adams P et al. Brief screening for family psychiatric history: the Family History Screen. Arch Gen Psychiatry 2000;57:675-82.
- 240. Esterberg ML, Trotman HD, Holtzman C et al. The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis. Schizophr Res 2010;120:121-30.
- 241. Kakela J, Panula J, Oinas E et al. Family history of psychosis and social, occupational and global outcome in schizophrenia: a meta-analysis. Acta Psychiatr Scand 2014;130:269-78.
- 242. Immonen J, Jaaskelainen E, Korpela H et al. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv Psychiatry 2017;11:453-60.
- 243. Kowalec K, Lu Y, Sariaslan A et al. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. Mol Psychiatry (in press).
- 244. Mirdal GKM, Mednick SA, Schulsinger F et al. Perinatal complications in children of schizophrenic mothers. Acta Psychiatr Scand 1974;50:553-6.
- 245. McNeil TF, Kaij L. Obstetric factors in the development of schizophrenia: complications in the birth of preschizophrenics and in reproduction by schizophrenic parents In: Wynne LC, Cromwell RL, Matthysse S. (eds). The nature of schizophrenia. New York: Wiley, 1978:401-29.
- 246. Lewis SW, Murray RM. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. J Psychiatr Res 1987;21:413-21.
- 247. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytical review. Am J Psychiatry 2002;159:1080-92.
- 248. Davies C, Segre G, Estradé A et al. Prenatal and perinatal risk factors for psychosis: a meta-analysis. Lancet Psychiatry 2020;7:399-41.
- 249. Walshe M, McDonald C, Boydell J et al. Long-term maternal recall of obstetric complications in schizophrenia research. Psychiatry Res 2011;187:335-40.
- 250. Lewis SW, Murray RM, Owen MJ. Obstetric complications in schizophrenia: methodology and mechanisms In: Schulz SC, Tamminga CA. (eds). Schizophrenia: scientific progress. New York: Oxford University Press, 1989:56-68.
- 251. McNeil TF, Sjöström K. A comprehensive scale for assessing obstetric complications. Malmo: Lund University, 1994.
- 252. Breeman LD, Jaekel J, Baumann N et al. Preterm cognitive function into adulthood. Pediatrics 2015;136:415-23.
- 253. Karolis VR, Froudist-Walsh S, Kroll J et al. Volumetric grey matter alterations in adolescents and adults born very preterm suggest accelerated brain maturation. Neuroimage 2017;163:379-89.
- 254. Froudist-Walsh S, Bloomfield MA, Veronese M et al. The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. eLife 2017;6:e29088.
- 255. Radua J, Ramella-Cravaro V, Ioannidis JP et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018;17:49-66.
- 256. Belbasis L, Köhler C, Stefanis N et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand 2018;137:88-97.
- 257. Morgan C, Knowles G, Hutchinson G. Migration, ethnicity and psychoses: evidence, models and future directions. World Psychiatry 2019;18:247-58.
- 258. Guloksuz S, Rutten BP, Pries L-K et al. The complexities of evaluating the exposome in psychiatry: a data-driven illustration of challenges and some propositions for amendments. Schizophr Bull 2018;44:1175-9.
- 259. Hailes HP, Yu R, Danese A et al. Long-term outcomes of childhood sexual abuse: an umbrella review. Lancet Psychiatry 2019;6:830-9.
- 260. Pries L-K, Guloksuz S, Ten Have M et al. Evidence that environmental and familial risks for psychosis additively impact a multidimensional subthreshold psychosis syndrome. Schizophr Bull 2018;44:710-9.
- 261. Guloksuz S, Pries L-K, Delespaul P et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry 2019;18:173-82.
- 262. Thomas S, Höfler M, Schäfer I et al. Childhood maltreatment and treatment outcome in psychotic disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2019;140:295-312.
- 263. Bloomfield MA, Yusuf FN, Srinivasan R et al. Trauma-informed care for adult survivors of developmental trauma with psychotic and dissociative symptoms: a systematic review of intervention studies. Lancet Psychiatry 2020;7:449-62.
- 264. Bernstein DP, Fink L, Handelsman L et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994;151:1132-6.
- 265. Bifulco A, Brown GW, Harris TO . Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry 1994;35:1419-35.
- 266. Weissman MM, Pathak J, Talati A. Personal life events – a promising dimension for psychiatry in electronic health records. JAMA Psychiatry 2020;77:115-6.
- 267. Schäfer M, Korn S, Smith PK et al. Lonely in the crowd: recollections of bullying. Br J Dev Psychol 2004;22:379-94.
- 268. Thabrew H, de Sylva S, Romans S. Evaluating childhood adversity In: Fava GA, Sonino N, Wise TN. (eds). The psychosomatic assessment. Basel: Karger, 2012:35-57.
- 269. Brand RM, McEnery C, Rossell S et al. Do trauma-focussed psychological interventions have an effect on psychotic symptoms? A systematic review and meta-analysis. Schizophr Res 2018;195:
- 13-22.
- 270. Britto PR, Lye SJ, Proulx K et al. Nurturing care: promoting early childhood development. Lancet 2017;389:91-102.
- 271. Beards S, Gayer-Anderson C, Borges S et al. Life events and psychosis: a review and meta-analysis. Schizophr Bull 2013;39:740-7.
- 272. Shakoor S, Zavos HMS, Haworth CMA et al. Association between stressful life events and psychotic experiences in adolescence: evidence for gene-environment correlations. Br J Psychiatry 2018;208:532-8.
- 273. Bhavsar V, Boydell J, McGuire P et al. Childhood abuse and psychotic experiences – evidence for mediation by adulthood adverse life events. Epidemiol Psychiatr Sci 2017;28:300-9.
- 274. Lataster J, Myin-Germeys I, Lieb R et al. Adversity and psychosis: a 10-year prospective study investigating synergism between early and recent adversity in psychosis. Acta Psychiatr Scand 2012;125:388-99.
- 275. Brown G, Harris T. Life events and illness. New York: Guilford, 1989.
- 276. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res 1967;11:213-8.
- 277. Dohrenwend BS, Askenasy AR, Krasnoff L et al. Exemplification of a method for scaling life events: the PERI Life Events Scale. J Health Soc Behav 1978;19:205-29.
- 278. Butjosa A, Gómez-Benito J, Myin-Germeys I et al. Development and validation of the Questionnaire of Stressful Life Events (QSLE). J Psychiatr Res 2017;95:213-23.
- 279. DeVylder JE, Koyanagi A, Unick J et al. Stress sensitivity and psychotic experiences in 39 low- and middle-income countries. Schizophr Bull 2016;42:1353-62.
- 280. Rauschenberg C, van Os J, Cremers D et al. Stress sensitivity as a putative mechanism linking childhood trauma and psychopathology in youth’s daily life. Acta Psychiatr Scand 2017;136:373-88.
- 281. DeVylder JE, Ben-David S, Schobel SA et al. Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis. Psychol Med 2012;43:259-68.
- 282. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-96.
- 283. Tso IF, Grove TB, Taylor SF. Self-assessment of psychological stress in schizophrenia: preliminary evidence of reliability and validity. Psychiatry Res 2012;195:39-44.
- 284. Myin-Germeys I, Kasanova Z, Vaessen T et al. Experience sampling methodology in mental health research: new insights and technical developments. World Psychiatry 2018;17:123-32.
- 285. Marconi A, Di Forti M, Lewis CM et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42:1262-9.
- 286. van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014;10:767-91.
- 287. Large M, Mullin K, Gupta P et al. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry 2014;48:418-32.
- 288. Schoeler T, Petros N, Di Forti M et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry 2017;4:627-33.
- 289. Di Forti M, Quattrone D, Freeman TP et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019;6:427-36.
- 290. Hjorthoj CR, Baker A, Fohlmann A et al. Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis. Curr Pharm Des 2014;20:2205-11.
- 291. Rossi A, Galderisi S, Rocca P et al. Personal resources and depression in schizophrenia: the role of self-esteem, resilience and internalized stigma. Psychiatry Res 2017;256:359-64.
- 292. Rossi A, Galderisi S, Rocca P et al. The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. Eur Arch Psychiatry Clin Neurosci 2017;267:285-94.
- 293. Tian CH, Feng XJ, Yue M et al. Positive coping and resilience as mediators between negative symptoms and disability among patients with schizophrenia. Front Psychiatry 2019;10:641.
- 294. Meyer B. Coping with severe mental illness: relations of the Brief COPE with symptoms, functioning, and well-being. J Psychopathol Behav Assess 2001;23:265-77.
- 295. Ventura J, Subotnik KL, Ered A et al. The relationship of attitudinal beliefs to negative symptoms, neurocognition, and daily functioning in recent-onset schizophrenia. Schizophr Bull 2014;40:1308-18.
- 296. Mizuno Y, Wartelsteiner F, Frajo-Apor B. Resilience research in schizophrenia: a review of recent developments. Curr Opin Psychiatry 2016;29:218-23.
- 297. Hofer A, Mizuno Y, Frajo-Apor B et al. Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: cultural comparison in Austria and Japan. Schizophr Res 2016;171:86-91.
- 298. Ventura J, Nuechterlein KH, Subotnik KL et al. Self-efficacy and neurocognition may be related to coping responses in recent-onset schizophrenia. Schizophr Res 2004;69:343-52.
- 299. Harris K, Gooding P, Haddock G et al. Factors that contribute to psychological resilience to suicidal thoughts and behaviours in people with schizophrenia diagnoses: qualitative study. BJPsych Open 2019;5:e79.
- 300. Carver CS. You want to measure coping but your protocol’s too long: consider the Brief COPE. Int J Behav Med 1997;4:92-100.
- 301. Xie Y. Reliability and validity of the simplified Coping Style Questionnaire. Chinese J Clin Psychol 1998;6:114-5.
- 302. Magliano L, Fadden G, Madianos M et al. Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 1998;33:405-12.
- 303. Friborg O, Hjemdal O, Rosenvinge JH et al. A new rating scale for adult resilience: what are the central protective resources behind healthy adjustment? Int J Methods Psychiatr Res 2003;12:65-76.
- 304. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson resilience scale (CD-RISC). Depress Anxiety 2003;18:76-82.
- 305. Drayton M, Birchwood M, Trower P. Early attachment experience and recovery from psychosis. Br J Clin Psychol 1998;37:269-84.
- 306. Leamy M, Bird V, Le Boutillier C et al. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry 2011;199:445-52.
- 307. Stuart SR, Tansey L, Quayle E. What we talk about when we talk about recovery: a systematic review and best-fit framework synthesis of qualitative literature. J Mental Health 2017;26:291-304.
- 308. Slade M, Blackie L, Longden E. Personal growth in psychosis. World Psychiatry 2019;18:29-30.
- 309. Whitley R, Shepherd G, Slade M. Recovery colleges as a mental health innovation. World Psychiatry 2019;18:141-2.
- 310. Corrigan PW. The impact of stigma on severe mental illness. Cogn Behav Pract 1998;5:201-22.
- 311. Brohan E, Elgie R, Sartorius N et al. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res 2010;122:232-8.
- 312. Ran MS, Zhang TM, Wong IY et al. Internalized stigma in people with severe mental illness in rural China. Int J Soc Psychiatry 2018;64:9-16.
- 313. Zhang TM, Wong IY, Yu YH et al. An integrative model of internalized stigma and recovery-related outcomes among people diagnosed with schizophrenia in rural China. Soc Psychiatry Psychiatr Epidemiol 2019;54:911-8.
- 314. Clement S, Schauman O, Graham T et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med 2015;45:11-27.
- 315. Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res 2003;121:31-49.
- 316. Boyd JE, Adler EP, Otilingam PG et al. Internalized Stigma of Mental Illness (ISMI) scale: a multinational review. Compr Psychiatry 2014;55:221-31.
- 317. Slade M. Recovery research: the empirical evidence from England. World Psychiatry 2012;11:162-3.
- 318. Sorsdahl KR, Kakuma R, Wilson Z et al. The internalized stigma experienced by members of a mental health advocacy group in South Africa. Int J Soc Psychiatry 2012;58:55-61.
- 319. Thornicroft G, Mehta N, Clement S et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. Lancet 2016;387:1123-32.
- 320. Tsang HW, Ching SC, Tang KH et al. Therapeutic intervention for internalized stigma of severe mental illness: a systematic review and meta-analysis. Schizophr Res 2016;173:45-53.
- 321. Reed GM, Mendonça Correira J, Esparza P et al. The WPA-WHO Global Survey of Psychiatrists’ Attitudes Towards Mental Disorders Classification. World Psychiatry 2011;10:118-31.
- 322. Kishimoto T, Hagi K, Nitta M et al. Long-term effectiveness of oral second-generation antipsychotics in patient with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 2019;18:208-24.
- 323. Dixon LB, Dickerson F, Bellack AS et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36:48-70.
- 324. Stovell D, Morrison AP, Panayiotou M et al. Shared treatment decision-making and empowerment-related outcomes in psychosis: systematic review and meta-analysis. Br J Psychiatry 2016;209:23-28.